Cáncer de páncreas: segunda línea, ¿tenemos ahora una opción real de secuenciación?

10 / 24

CONKO-003 trial
• Phase III trial
• Progression during first-line gemcitabine monotherapy were eligible
• Study conducted at 16 sites throughout Germany
• N 160 patients advanced disease (88% M1)
• FF comprised intravenous (IV) folinic acid 200 mg/m2 followed by a continuous IV
infusion of fluorouracil 2,000 mg/m2 over 24 hours on days 1, 8, 15, and 22. OFF
comprised FF and oxaliplatin 85 mg/m2 IV administered before FF on days 8 and
22
• Recruitment period from January 2004 until May 2007 (> 3 y)
• Post-progression treatment 25% (OFF 22, FF 18).
Oettle et al. JCO 2014;32:2423-9